Tenderwize
Zurück zur Suche

Open House Drug Discount Agreement Posaconazole

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 05, 2027 · 220 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Posaconazol, ATC J02AC04

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

30 / 100

Risikofaktoren

No contract value or volume is disclosed. Potential revenue is unknown.

The open-house agreement automatically suspends if a competitive discount contract for the same substance comes into ef...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for Posaconazole (ATC J02AC04) with AOK Bayern.
  • Pharmaceutical companies must supply Posaconazole products and adhere to the discount terms set in the contract.
Vollständige Zusammenfassung anzeigen

This is an open-house model (non-competitive) for non-exclusive drug discount agreements for Posaconazole (ATC J02AC04) by AOK Bayern. Any eligible pharmaceutical company can join at any time during the contract period. The contract runs from 01.06.2025 to 31.05.2027. No estimated value is provided. Eligibility requires a signed self-declaration of reliability. Submission can be in paper form (2 copies) or electronically with a qualified electronic signature via the DTVP portal. The notice explicitly states this is not a public procurement procedure under EU procurement law.

Risiken

No contract value or volume is disclosed. Potential revenue is unknown.

The open-house agreement automatically suspends if a competitive discount contract for the same substance comes into ef...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • Must submit a signed self-declaration of reliability (downloaded from the procurement portal).
  • The signed contract and annex 'Specification of the contract drugs' must be submitted along with the self-declaration.

Zuschlagskriterien

Lot 1

No award criteria are specified as this is an open-house model with no competitive selection.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Drug Discount Agreement Posaconazole

Non-exclusive discount agreements for the active substance Posaconazole (ATC J02AC04). The contract is open to all interested pharmaceutical companies that meet the eligibility criteria. Contracts can be concluded at any time up to 05.04.2027, with earliest start 01.06.2025 and all contracts ending 31.05.2027.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria are specified as this is an open-house model with no competitive selection.

Frist

Deadline Apr 05, 2027

Vergabedetails

Veröffentlichungsdatum
15 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
248660-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30